Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Bioregenx (BRGX) Cost of Revenue (2023 - 2025)

Bioregenx (BRGX) has 3 years of Cost of Revenue data on record, last reported at $81358.0 in Q3 2025.

  • For Q3 2025, Cost of Revenue fell 28.88% year-over-year to $81358.0; the TTM value through Sep 2025 reached $421740.0, down 50.03%, while the annual FY2024 figure was $681685.0, 38.03% down from the prior year.
  • Cost of Revenue reached $81358.0 in Q3 2025 per BRGX's latest filing, down from $93514.0 in the prior quarter.
  • Across five years, Cost of Revenue topped out at $311694.0 in Q1 2023 and bottomed at $81358.0 in Q3 2025.
  • Average Cost of Revenue over 3 years is $187787.3, with a median of $165390.0 recorded in 2024.
  • Peak YoY movement for Cost of Revenue: dropped 0.31% in 2024, then plummeted 64.6% in 2025.
  • A 3-year view of Cost of Revenue shows it stood at $299983.0 in 2023, then crashed by 54.08% to $137752.0 in 2024, then plummeted by 40.94% to $81358.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Cost of Revenue were $81358.0 in Q3 2025, $93514.0 in Q2 2025, and $109116.0 in Q1 2025.